The findings confirmed that plasma Aβ42 and tau levels detected by IMR technology achieved exceptional accuracy of diagnosis and thus have potential to be further developed as blood biomarkers for assisting in the clinical diagnosis of AD. The gene discussed is MAPT; the disease is Alzheimer disease.